Equities researchers at Jefferies Financial Group began coverage on shares of Rapport Therapeutics (NASDAQ:RAPP – Get Free Report) in a note issued to investors on Tuesday, Briefing.com reports. The firm set a “buy” rating and a $35.00 price target on the stock.
Separately, Stifel Nicolaus assumed coverage on Rapport Therapeutics in a report on Tuesday. They issued a “buy” rating and a $35.00 target price for the company.
Read Our Latest Report on Rapport Therapeutics
Rapport Therapeutics Price Performance
Want More Great Investing Ideas?
Read More
- Five stocks we like better than Rapport Therapeutics
- Upcoming IPO Stock Lockup Period, Explained
- Snowflake Stock Rebounds, Flies Higher on AI Spending
- How to Use the MarketBeat Excel Dividend Calculator
- Complete Solaria, Senti, and POET: 3 High Volume Penny Stocks
- Following Congress Stock Trades
- Pfizer Stock is Ready to Stage a Turnaround on GLP-1 Hopes
Receive News & Ratings for Rapport Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rapport Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
